

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. to 35. (CANCELED)

36. *(previously presented)*: A method of treating systemic inflammatory response syndrome (SIRS) in a human subject in need thereof, the method comprising:

- (a) selecting a human subject having a risk genotype for SIRS, which subject has one of more of the following genotypes at one or more of the following positions:
 - (i) CC or CT at 4732 of SEQ ID NO:1;
 - (ii) TT or TC at 4054 of SEQ ID NO:2,
 - (iii) AA or AG at 2418 of SEQ ID NO:1, or
 - (iv) a genotype in linkage disequilibrium (LD) with position 4732; 4054; and 2418 as follows:
 - (1) for sites in LD with position 4732 of SEQ ID NO:1: AA or AG at 4813, GG or GA at 6379, AA or AG at 6762, CC or C- at 7779, TT or TC at 8058, TT or TG at 8915 or TT or TC at 12228 of SEQ ID NO:1;
 - (2) for sites in LD with position 4054 of SEQ ID NO:2: CC or CT at 2973, GG or GA at 3063, GG or GC at 3402, TT or TC at 4946, TT or TC at 5515 or GG or GC at 6196 of SEQ ID NO:2; or
 - (3) for sites in LD with position 2418 of SEQ ID NO:1: TT or TC at 1386, AA or AT at 2583 or TT or TC at 3920 in SEQ ID NO:1; or
- (v) a combination of genotypes in SEQ ID NO:1 which are in LD with position 4732 in SEQ ID NO:1 selected from the group of genotypes at positions consisting of:
 - (1) CC or CA at 9198 and AA or AG at 5867;
 - (2) CC or CA at 9198 and GG or GC at 4800;
 - (3) AA or AG at 3220 and AA or AG at 5867; and
 - (4) AA or AG at 3220 and GG or GC of 4800;
- (vi) a combination of genotypes in SEQ ID NO:1 which are in LD with position 2418 in SEQ ID NO:1, selected from the group of genotypes at positions consisting of:

- (1) AA or AG at 5867 and TT or TC at 2405;
- (2) AA or AG at 5867 and AA or AG at 4919;
- (3) AA or AG at 5867 and TT or TC at 4956;
- (4) AA or AG at 5867 and CC or CT at 6187;
- (5) AA or AG at 5867 and TT or TC at 12109;
- (6) GG or GC at 4800 and TT or TC at 2405;
- (7) GG or GC at 4800 and AA or AG at 4919;
- (8) GG or GC at 4800 and TT or TC at 4956;
- (9) GG or GC at 4800 and CC or CT at 6187; and
- (10) GG or GC at 4800 and TT or TC at 12109, and

(b) administering to said human subject selected in (a) an activated protein C.

37 to 43: CANCELED

44. *(previously presented)*: The method at claim 36, further comprising determining the subject's APACHE II score as an assessment of subject risk.

45. *(previously presented)*: The method of claim 36, further comprising determining the number of organ system failures for the subject as an assessment of subject risk.

46. *(previously presented)*: The method of claim 44, wherein, an APACHE II score ≥ 25 is indicative of increased risk.

47. *(previously presented)*: The method of claim 45, wherein two or more organ system failures are indicative of increased subject risk.

48. to 59. (CANCELED)

60. *(previously presented)*: The method of claim 36, wherein the genotype of the subject is indicative of an increased risk of poor outcome from the SIRS.

61. *(previously presented)*: The method of claim 60, wherein the subject who has an increased risk of poor outcome from SIRS is preferentially selected for administration of the activated protein C.

62 to 67. (CANCELED)

68. *(previously presented)*: The method of claim 36, wherein the activated protein C is drotrecogin alfa activated.

69 to 87: (CANCELED)

88. *(previously presented)*: The method of claim 36, wherein the risk genotype is located at a polymorphic site at one or both positions 4732 of SEQ ID NO:1 and 4054 of SEQ ID NO:2.

89. to 91. (CANCELED)

92. *(previously presented)*: The method of claim 36, wherein the human subject has sepsis.

93. *(previously presented)*: The method of claim 36, wherein the human subject has septic shock.